Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

Trial Profile

Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Huperzine A (Primary)
  • Indications Seizures
  • Focus Proof of concept; Therapeutic Use
  • Acronyms FIAS
  • Sponsors Biscayne Neurotherapeutics
  • Most Recent Events

    • 28 Mar 2018 According to Biscayne Neurotherapeutics media release, results are expected later in 2018.
    • 21 Mar 2018 Status changed from planning to recruiting.
    • 19 Oct 2017 According to a Biscayne Neurotherapeutics media release, this trial is expected to begin in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top